Search

Your search keyword '"Beuselinck B"' showing total 301 results
Start Over Author "Beuselinck B"
301 results on '"Beuselinck B"'

3. 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study

Author

Ajuria, L. Carril, primary, Naigeon, M., additional, Flippot, R., additional, Dalban, C., additional, Desnoyer, A., additional, Rioux-Leclercq, N., additional, Sautes-Fridman, C., additional, Meylan, M., additional, Vano, Y., additional, Beuselinck, B., additional, Chouaib, S., additional, de Oliveira, C., additional, Tantot, F., additional, Escudier, B., additional, Chaput-Gras, N., additional, and Albiges, L., additional

Published
2023
Full Text
View/download PDF

4. Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, K., Yuasa, T., Lemelin, A., Ferrier, E., Wells, J.C., Saad, E., Saliby, R.M., Basappa, N.S., Wood, L.A., Jude, E., Pal, S.K., Donskov, F., Beuselinck, B., Szabados, B., Powles, T., McKay, R.R., Gebrael, G., Agarwal, N., Choueiri, T.K., and Heng, D.Y.C.

Published
2024
Full Text
View/download PDF

5. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors

Author

van Cann, T., Loyson, T., Verbiest, A., Clement, P. M., Bechter, O., Willems, L., Spriet, I., Coropciuc, R., Politis, C., Vandeweyer, R. O., Schoenaers, J., Debruyne, P. R., Dumez, H., Berteloot, P., Neven, P., Nackaerts, K., Woei-A-Jin, F. J. S. H., Punie, K., Wildiers, H., and Beuselinck, B.

Published
2017
Full Text
View/download PDF

7. 1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC)

Author

Takemura, K., primary, Navani, V., additional, Ernst, M.S., additional, Wells, J.C., additional, Choueiri, T.K., additional, Meza, L., additional, Pal, S.K., additional, Lee, J-L., additional, Li, H., additional, Agarwal, N., additional, Alva, A.S., additional, Hansen, A.R., additional, Basappa, N.S., additional, Szabados, B.E., additional, Powles, T.B., additional, Tran, B., additional, Hocking, C.M., additional, Beuselinck, B., additional, Yuasa, T., additional, and Heng, D.Y.C., additional

Published
2022
Full Text
View/download PDF

9. 1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)

Author

Navani, V., primary, Ernst, M.S., additional, Takemura, K., additional, Pal, S.K., additional, Powles, T.B., additional, Donskov, F., additional, Wells, J.C., additional, Kollmannsberger, C.K., additional, Beuselinck, B., additional, Alva, A.S., additional, Weickhardt, A.J., additional, Lalani, A-K., additional, Ernst, D.S., additional, Agarwal, N., additional, Choueiri, T.K., additional, and Heng, D.Y.C., additional

Published
2022
Full Text
View/download PDF

10. Expanding the Role of Ultrasound for the Characterization of Renal Masses

Author

Roussel, E., Campi, R., Amparore, D., Bertolo, R., Carbonara, U., Erdem, S., Ingels, A., Kara, Ö., Marandino, L., Marchioni, M., Muselaers, S., Pavan, N., Pecoraro, A., Beuselinck, B., Pedrosa, I., Fetzer, D., Albersen, M., Roussel, E., Campi, R., Amparore, D., Bertolo, R., Carbonara, U., Erdem, S., Ingels, A., Kara, Ö., Marandino, L., Marchioni, M., Muselaers, S., Pavan, N., Pecoraro, A., Beuselinck, B., Pedrosa, I., Fetzer, D., and Albersen, M.

Abstract

Item does not contain fulltext, The incidental detection of renal masses has been steadily rising. As a significant proportion of renal masses that are surgically treated are benign or indolent in nature, there is a clear need for better presurgical characterization of renal masses to minimize unnecessary harm. Ultrasound is a widely available and relatively inexpensive real-time imaging technique, and novel ultrasound-based applications can potentially aid in the non-invasive characterization of renal masses. Evidence acquisition: We performed a narrative review on novel ultrasound-based techniques that can aid in the non-invasive characterization of renal masses. Evidence synthesis: Contrast-enhanced ultrasound (CEUS) adds significant diagnostic value, particularly for cystic renal masses, by improving the characterization of fine septations and small nodules, with a sensitivity and specificity comparable to magnetic resonance imaging (MRI). Additionally, the performance of CEUS for the classification of benign versus malignant renal masses is comparable to that of computed tomography (CT) and MRI, although the imaging features of different tumor subtypes overlap significantly. Ultrasound molecular imaging with targeted contrast agents is being investigated in preclinical research as an addition to CEUS. Elastography for the assessment of tissue stiffness and micro-Doppler imaging for the improved detection of intratumoral blood flow without the need for contrast are both being investigated for the characterization of renal masses, though few studies have been conducted and validation is lacking. Conclusions: Several novel ultrasound-based techniques have been investigated for the non-invasive characterization of renal masses. CEUS has several advantages over traditional grayscale ultrasound, including the improved characterization of cystic renal masses and the potential to differentiate benign from malignant renal masses to some extent. Ultrasound molecular imaging offers promise for serial di

Published
2022

11. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Author

Laureano, R.S., Sprooten, J., Vanmeerbeerk, I., Borras, D.M., Govaerts, J., Naulaerts, S., Berneman, Z.N., Beuselinck, B., Bol, K.F., Borst, J., Coosemans, A., Datsi, A., Fučíková, J., Kinget, L., Neyns, B., Schreibelt, G., Smits, E., Sorg, R.V., Spisek, R., Thielemans, K., Tuyaerts, S., Vleeschouwer, S. De, Vries, I.J.M. de, Xiao, Y., Garg, A.D., Laureano, R.S., Sprooten, J., Vanmeerbeerk, I., Borras, D.M., Govaerts, J., Naulaerts, S., Berneman, Z.N., Beuselinck, B., Bol, K.F., Borst, J., Coosemans, A., Datsi, A., Fučíková, J., Kinget, L., Neyns, B., Schreibelt, G., Smits, E., Sorg, R.V., Spisek, R., Thielemans, K., Tuyaerts, S., Vleeschouwer, S. De, Vries, I.J.M. de, Xiao, Y., and Garg, A.D.

Abstract

Contains fulltext : 283345.pdf (Publisher’s version ) (Open Access), Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8(+)/CD4(+) T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.

Published
2022

13. Prognostic impact of clear cell renal cell carcinoma molecular subtypes determined on formalin-fixed paraffin-embedded tissue samples on outcome after complete surgical metastasectomy

Author

Roussel, E., primary, Kinget, L., additional, Verbiest, A., additional, Boeckx, B., additional, Couchy, G., additional, Caruso, S., additional, Zucman-Rossi, J., additional, Baldewijns, M., additional, Joniau, S., additional, Van Poppel, H., additional, Lambrechts, D., additional, Albersen, M., additional, and Beuselinck, B., additional

Published
2022
Full Text
View/download PDF

15. 687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab

Author

Carril Ajuria, L., primary, Naigeon, M., additional, Dalban, C., additional, Desnoyer, A., additional, Rioux-Leclercq, N., additional, Sautès-Fridman, C., additional, Meylan, M., additional, Vano, Y., additional, Beuselinck, B., additional, Chouaib, S., additional, de Oliveira, C., additional, Tantot, F., additional, Escudier, B., additional, Albiges, L., additional, and Chaput, N., additional

Published
2021
Full Text
View/download PDF

16. 689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)

Author

Kinget, L., primary, Roussel, E., additional, Lambrechts, D., additional, Boeckx, B., additional, Verbiest, A.T.L., additional, Zucman-Rossi, J., additional, Couchy, G., additional, Dalban, C., additional, Meylan, M., additional, Chabaud, S., additional, Vano, Y., additional, Sautès-Fridman, C., additional, Fridman, W-H., additional, Baldewijns, M., additional, Albersen, M., additional, Rioux-Leclercq, N., additional, Tantot, F., additional, Chaput, N., additional, Beuselinck, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

19. NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab

Author

Ajuria, L. Carril, Naigeon, M., Dalban, C., Desnoyer, A., Rioux-Leclercq, N., Sautes-Fridman, C., Meylan, M., Vano, Y., Beuselinck, B., Chouaib, S., De Oliveira, C., Tantot, Olivier, Escudier, B., Albiges, L., Chaput, N., Institut Gustave Roussy (IGR), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), UNICANCER, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), University Hospitals Leuven [Leuven], Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Oncologie génito-urinaire, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Laboratoire d’Immunomonitoring en Oncologie (LIO), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut National du CancerInstitut National du Cancer (INCA) France, Bristol-Myers SquibbBristol-Myers Squibb, Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), and Chard-Hutchinson, Xavier

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021

20. Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)

Author

Kinget, L., Roussel, E., Lambrechts, D., Boeckx, B., Verbiest, A. T. L., Zucman-Rossi, Jessica, Couchy, G., Dalban, C., Meylan, M., Chabaud, S., Vano, Y., Sautes-Fridman, C., Fridman, W-H., Baldewijns, M., Albersen, M., Rioux-Leclercq, N., Tantot, F., Chaput, N., Beuselinck, B., Albiges, L., University Hospitals Leuven [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Vlaams Instituut voor Biotechnologie [Ghent, Belgique] (VIB), Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine, ex- Institut Universitaire Hématologie-IUH) (IRSL), Université de Paris (UP), Centre Léon Bérard [Lyon], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), UNICANCER, Intégrité du génome et cancers (IGC), Institut Gustave Roussy (IGR)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), Institut National du CancerInstitut National du Cancer (INCA) France, Bristol-Myers-SquibbBristol-Myers Squibb, 'Kom op tegen Kanker' (Stand up to Cancer), Flemish Cancer Society, Université Paris Cité (UPCité), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Département de médecine oncologique [Gustave Roussy], and Chard-Hutchinson, Xavier

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021

21. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study

Author

Wells, JC, Dudani, S, Gan, CL, Stukalin, I, Azad, AA, Liow, E, Donskov, F, Yuasa, T, Pal, SK, De Velasco, G, Hansen, AR, Beuselinck, B, Kollmannsberger, CK, Powles, T, McGregor, BA, Duh, MS, Huynh, L, Heng, DYC, Wells, JC, Dudani, S, Gan, CL, Stukalin, I, Azad, AA, Liow, E, Donskov, F, Yuasa, T, Pal, SK, De Velasco, G, Hansen, AR, Beuselinck, B, Kollmannsberger, CK, Powles, T, McGregor, BA, Duh, MS, Huynh, L, and Heng, DYC

Abstract

BACKGROUND: Limited data exist on the clinical effectiveness of second-line (2L) vascular endothelial growth factor (receptor) targeted inhibitor (VEGF(R)i) sunitinib after first-line (1L) immuno-oncology (IO) therapy for patients with metastatic renal cell carcinoma (mRCC) in real-world settings. METHODS: A retrospective cohort study among adult patients with mRCC treated with 2L sunitinib following 1L IO was conducted from select International mRCC Database Consortium (IMDC) centers. All analyses were performed overall and by 1L ipilimumab + nivolumab (IPI+NIVO) or 1L IO+VEGF(R)i. Median overall survival (mOS) and time-to-treatment discontinuation (mTTD) in 2L were estimated using Kaplan-Meier analysis. The 2L objective response rate (ORR) (complete/partial response) was reported. RESULTS: Among 102 patients on 2L sunitinib, mean age was 61.3 years. IMDC risk scores at 2L initiation was available for 83 patients: 8 (9.6%) were favorable, 45 (54.2%) were intermediate, and 30 (36.1%) were poor risk. The 1L consisted of IPI+NIVO in 62 (60.8%), IO+VEGF(R)i therapy in 27 (26.5%), and IO monotherapy in 13 (12.7%) patients. Among all patients, mOS was 15.6 months (95% confidence interval [CI], 9.8-21.7), with a 1-year OS rate of 57.5% (95% CI, 45.2-68.0). mTTD was 5.4 months (95% CI, 4.2-7.2) and ORR was 22.5%. CONCLUSION: Despite availability of effective 1L therapies in recent years, 2L sunitinib continues to have clinical activity after failure of 1L IO. Further studies on optimal treatment sequencing after 1L IO progression are needed.

Published
2021

22. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Gan, CL, Dudani, S, Wells, JC, Donskov, F, Pal, SK, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A-KA, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, JL, Vaishampayan, UN, Bjarnason, GA, Subasri, M, Choueiri, TK, Heng, DYC, Gan, CL, Dudani, S, Wells, JC, Donskov, F, Pal, SK, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A-KA, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, JL, Vaishampayan, UN, Bjarnason, GA, Subasri, M, Choueiri, TK, and Heng, DYC

Abstract

BACKGROUND: Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real-world effectiveness and dosing patterns of cabozantinib are not well characterized. METHODS: Patients with mRCC treated with cabozantinib between 2011 and 2019 were identified and stratified using the International mRCC Database Consortium (IMDC) risk groups. First- (1L), second- (2L), third- (3L), and fourth-line (4L) overall response rate (ORR), time to treatment failure (TTF), and overall survival (OS) were analyzed. Dose reduction rates and their association with TTF and OS were determined. RESULTS: A total of 413 patients were identified. The ORRs across 1L to 4L were 32%, 26%, 25%, and 29%, respectively, and the median TTF rates were 8.3, 7.3, 7.0, and 8.0 months, respectively. The median OS (mOS) rates in 1L to 4L were 30.7, 17.8, 12.6, and 14.9 months, respectively. For patients treated with 1L PD(L)1 combination agent (n = 31), 2L cabozantinib had ORR of 22%, median TTF of 5.4 months, and mOS of 17.4 months. About 50% (129/258) of patients required dose reductions. The TTF and mOS were significantly longer for patients who required dose reduction vs. patients who did not, with an adjusted hazard ratio of 0.37 (95% CI 0.202-0.672, p < 0.01) and 0.46 (95% CI 0.215-0.980, p = 0.04), respectively. Limitations include the retrospective study design and the lack of central radiology review. CONCLUSION: The ORR and TTF of cabozantinib were maintained from the 1L to 4L settings. Dose reductions due to toxicity were associated with improved TTF and OS. Cabozantinib has clinical activity after 1L Immuno-oncology combination agents.

Published
2021

24. 1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

Author

Lemelin, A., Takemura, K., Boyne, D.J., Warkentin, M.T., Brenner, D.R., Cheun, W.Y., Wells, J.C., Labaki, C., McGregor, B.A., Basappa, N.S., Meza, L.A., Pal, S.K., Beuselinck, B., McKay, R.R., Szabados, B.E., Powles, T.B., Yuasa, T., Ludwig, L., Choueiri, T.K., and Heng, D.Y.C.

Published
2023
Full Text
View/download PDF

26. An update on the management of metastatic clear-cell renal cell carcinoma : the BSMO expert panel recommendations

Author

Delafontaine, B, De Backer, C, Beuselinck, B, Debruyne, P, D'Hondt, Lionel, UCL - (MGD) Service d'oncologie médicale, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Abstract

The management of recurrent or metastatic renal cell carcinoma is evolving fast, with new therapeutic options becoming available that may improve the outcome of patients. In this paper, recent evolutions are discussed and recommendations are made regarding the management of renal cell carcinoma in a Belgian context.

Published
2020

27. Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)

Author

Meylan, M., Beuselinck, B, Dalban, C., Vano, Y., Leclercq, N. Rioux, Sautès-Fridman, C., Roussel, E., Verbiest, A, Chaput, N., Terry, S., Chevreau, C., Gross-Goupil, M., Flechon, A, Laguerre, B., Chabaud, S., Tantot, F., Lambrechts, D., Escudier, B., Fridman, W.-H., Albiges, L., Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), University Hospitals Leuven [Leuven], Centre Léon Bérard [Lyon], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Institut Gustave Roussy (IGR), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay, Institut Claudius Regaud, CHU Bordeaux [Bordeaux], Centre Eugène Marquis (CRLCC), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), UNICANCER, Leuven Center for Cancer Biology (VIB-KU-CCB), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)-Vlaams Instituut voor Biotechnologie [Ghent, Belgique] (VIB), Institut National du CancerInstitut National du Cancer (INCA) France, Bristol-Myers SquibbBristol-Myers Squibb, École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

28. Corrigendum to “Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis”

Author

Schöffski, P., primary, Timmermans, I., additional, Hompes, D., additional, Stas, M., additional, Boecxstaens, Veerle, additional, Sinnaeve, F., additional, De Leyn, P., additional, Coosemans, W., additional, Van Raemdonck, D., additional, Hauben, E., additional, Sciot, R., additional, Clement, P., additional, Bechter, O., additional, Beuselinck, B., additional, Woei-A-Jin, F. J. S. H., additional, Dumez, H., additional, Nafteux, P., additional, and Wessels, T., additional

Published
2021
Full Text
View/download PDF

32. 700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)

Author

Meylan, M., primary, Beuselinck, B., additional, Dalban, C., additional, Vano, Y., additional, Rioux Leclercq, N., additional, Sautès-Fridman, C., additional, Roussel, E., additional, Verbiest, A., additional, Chaput, N., additional, Terry, S., additional, Chevreau, C., additional, Gross-Goupil, M., additional, Fléchon, A., additional, Laguerre, B., additional, Chabaud, S., additional, Tantot, F., additional, Lambrechts, D., additional, Escudier, B., additional, Fridman, W-H., additional, and Albiges, L., additional

Published
2020
Full Text
View/download PDF

33. The role of cytoreductive nephrectomy in the contemporary management of metastatic kidney cancer: Predictive factors for surgical complications and oncological survival

Author

Roussel, E., primary, Verbiest, A., additional, Milenkovic, U., additional, Everaerts, W., additional, Van Cleynenbreugel, B., additional, Van Poppel, H., additional, Joniau, S., additional, Beuselinck, B., additional, Devos, G., additional, Muilwijk, T., additional, and Albersen, M., additional

Published
2020
Full Text
View/download PDF

34. Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma

Author

Wells, J.C., primary, Dudani, S., additional, Gan, C.L., additional, Stukalin, I., additional, Azad, A., additional, Liow, E., additional, Donskov, F., additional, Yuasa, T., additional, Pal, S., additional, De Velasco, G., additional, Wood, L., additional, Hansen, A., additional, Beuselinck, B., additional, Kollmannsberger, C., additional, Powles, T., additional, Mcgregor, B., additional, Duh, M.S., additional, Huynh, L., additional, and Heng, D.Y.C., additional

Published
2020
Full Text
View/download PDF

35. Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis

Author

Schöffski, P., primary, Timmermans, I., additional, Hompes, D., additional, Stas, M., additional, Sinnaeve, F., additional, De Leyn, P., additional, Coosemans, W., additional, Van Raemdonck, D., additional, Hauben, E., additional, Sciot, R., additional, Clement, P., additional, Bechter, O., additional, Beuselinck, B., additional, Woei-A-Jin, F. J. S. H., additional, Dumez, H., additional, Nafteux, P., additional, and Wessels, T., additional

Published
2020
Full Text
View/download PDF

36. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Author

Tykodi S.S., Carducci M.A., Heng D.Y.C., Kollmannsberger C.K., Harrison M.R., Tomita Y., Duran I., Grunwald V., McHenry M.B., Mekan S., Tannir N.M., Motzer R.J., Rini B.I., McDermott D.F., Aren Frontera O., Salman P., Escudier B., Beuselinck B., Amin A., Porta C., George S., Neiman V., Bracarda S., Hammers H.J., Barthelemy P., Leibowitz-Amit R., Plimack E.R., Oosting S.F., Redman B., Melichar B., Powles T., Nathan P., Oudard S., Pook D., Choueiri T.K., Donskov F., Grimm M.-O., Gurney H., Tykodi S.S., Carducci M.A., Heng D.Y.C., Kollmannsberger C.K., Harrison M.R., Tomita Y., Duran I., Grunwald V., McHenry M.B., Mekan S., Tannir N.M., Motzer R.J., Rini B.I., McDermott D.F., Aren Frontera O., Salman P., Escudier B., Beuselinck B., Amin A., Porta C., George S., Neiman V., Bracarda S., Hammers H.J., Barthelemy P., Leibowitz-Amit R., Plimack E.R., Oosting S.F., Redman B., Melichar B., Powles T., Nathan P., Oudard S., Pook D., Choueiri T.K., Donskov F., Grimm M.-O., and Gurney H.

Abstract

Background: In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting. Method(s): In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status into favourable-risk, intermediate-risk, and poor-risk subgroups and randomly assigned (1:1) to open-label nivolumab (3 mg/kg intravenously) plus ipilimumab (1 mg/kg intravenously) every 3 weeks for four doses, followed by nivolumab (3 mg/kg intravenously) every 2 weeks; or sunitinib (50 mg orally) once daily for 4 weeks (6-week cycle). Randomisation was done through an interactive voice response system, with a block size of four and stratified by risk status and geographical region. The co-primary endpoints for the trial were overall survival, progression-free survival per independent radiology review committee (IRRC), and objective responses per IRRC in intermediate-risk or poor-risk patients. Secondary endpoints were overall survival, progression-free survival per IRRC, and objective responses per IRRC in the intention-to-treat population, and adverse events in all treated patients. In this Article, we report overall survival, investigator-assessed progression-free survival, investigator-assessed objective response, characterisation of response, and safety after extended follow-up. Efficacy outcomes were assessed in all randomly assig

Published
2019

37. Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)

Author

Stukalin, I. Connor Wells, J. Fraccon, A. Pasini, F. Porta, C. Lalani, A.-K.A. Srinivas, S. Alex Bowman, I. Brugarolas, J. Lee, J.-L. Donskov, F. Beuselinck, B. Bamias, A. Rini, B.I. Sim, H.-W. Agarwal, N. Rha, S.-Y. Kanesvaran, R. Choueiri, T.K. Heng, D.Y.C.

Abstract

Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC Database Consortium (IMDC) dataset was used to identify patients with mRCC treated with 4LT. This is a multicenter, retrospective cohort study. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier curves. Patients were evaluated for overall response. The six prognostic variables included in the IMDC prognostic model were used to stratify patients into favorable-, intermediate- and poor-risk groups. Exploratory analyses were performed examining the elderly (>70 years old) and non-clear cell RCC subgroups. Proportional hazards regression modelling was performed adjusting these covariates by IMDC criteria measured at initiation of 4th line therapy. Results: 7498 patients were treated with first line targeted therapy and out of these 594 (7.9%) received 4LT. Everolimus was the most frequently used 4LT (16.8%). Sorafenib, axitinib, pazopanib, sunitinib and clinical trial drugs were also used in >10% of patients. The OS of patients on any 4LT was 12.8 months, with a PFS of 4.4 months. The overall response rate (ORR) was 13.7%. Favorable-risk patients using IMDC criteria (5%) displayed an OS of 23.1 months, intermediate-risk patients (66%) had an OS of 13.8 months and poor-risk patients (29%) had an OS of 7.8 (p < 0.0001) months. Age >70 years and non-clear cell histology did not impact OS. Our study is limited by its retrospective design. Conclusions: 4LT use appears to have activity in mRCC patients. The IMDC continues to be of prognostic value in the fourth-line setting for OS. This study helps to set a benchmark for response rate and survival for which clinical trials can plan sample size calculations and aim to improve upon. © 2018 - IOS Press and the authors. All rights reserved

Published
2018

38. NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

Author

Vano, Y., primary, Rioux-Leclercq, N., additional, Dalban, C., additional, Sautès-Fridman, C., additional, Bougoüin, A., additional, Chaput, N., additional, Chouaib, S., additional, Beuselinck, B., additional, Chevreau, C.M., additional, Gross-Goupil, M., additional, Negrier, S., additional, Laguerre, B., additional, Borchiellini, D., additional, Colina-Moreno, I., additional, Fridman, W.H., additional, Chabaud, S., additional, Tantot, F., additional, Barros Monteiro, J., additional, Escudier, B., additional, and Albiges, L., additional

Published
2019
Full Text
View/download PDF

39. Advanced clear-cell renal cell carcinoma (accRCC): Association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome

Author

Verbiest, A.T.L., primary, Van Hoef, V., additional, Lambrechts, D., additional, Rodriguez Antona, C., additional, Grana-Castro, O., additional, Inglada-Perez, L., additional, Albersen, M., additional, Baldewijns, M., additional, Laenen, A., additional, Schoeffski, P., additional, Wozniak, A., additional, Couchy, G., additional, Caruso, S., additional, Zucman-Rossi, J., additional, and Beuselinck, B., additional

Published
2019
Full Text
View/download PDF

40. Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

Author

Desnoyer, A., primary, Larive, A., additional, Drubay, D., additional, Lanoy, E., additional, Vano, Y., additional, Rioux-Leclercq, N., additional, Chouaib, S., additional, Beuselinck, B., additional, Tantot, F., additional, Escudier, B., additional, Chaput, N., additional, and Albiges, L., additional

Published
2019
Full Text
View/download PDF

41. Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Stukalin, I., primary, Wells, J.C., additional, Graham, J., additional, Yuasa, T., additional, Beuselinck, B., additional, Kollmansberger, C., additional, Ernst, D.S., additional, Agarwal, N., additional, Le, T., additional, Donskov, F., additional, Hansen, A.R., additional, Bjarnason, G.A., additional, Srinivas, S., additional, Wood, L.A., additional, Alva, A.S., additional, Kanesvaran, R., additional, Fu, S.Y.F., additional, Davis, I.D., additional, Choueiri, T.K., additional, and Heng, D.Y.C., additional

Published
2019
Full Text
View/download PDF

43. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)

Author

Yip, S.M. Ruiz Morales, J.M. Donskov, F. Fraccon, A. Basso, U. Rini, B.I. Lee, J.L. Bjarnason, G.A. Sim, H.-W. Beuselinck, B. Kanesvaran, R. Brugarolas, J. Koutsoukos, K. Fu, S.Y.F. Yuasa, T. Davis, I. Alva, A. Kollmannsberger, C. Choueiri, T.K. Heng, D.Y.C.

Abstract

Background: Treatment outcomes are poorly characterized in patients with metastatic chromophobe renal cell cancer (chrRCC), a subtype of renal cell carcinoma. Objective: This retrospective series aims to determine metastatic chrRCC treatment outcomes in the targeted therapy era. Methods: A retrospective data analysis was performed using the IMDC dataset of 4970 patients to determine metastatic chrRCC treatment outcomes in the targeted therapy era. Results: 109/4970 (2.2%) patients had metastatic chrRCC out of all patients with mRCC treated with targeted therapy. These patients were compared with 4861/4970 (97.8%) clear cell mRCC (ccRCC) patients. Patients with metastatic chrRCC had a similar OS compared to patients with ccRCC (23.8 months (95% CI 16.7 - 28.1) vs 22.4 months (95% CI 21.4 - 23.4), respectively (p = 0.0908). Patients with IMDC favorable (18%), intermediate (59%) and poor risk (23%) had median overall survivals of 31.4, 27.3, and 4.8 months, respectively (p = 0.028). Conclusions: To the authors' knowledge, this is the largest series of metastatic chrRCC patients and these results set new benchmarks for survival in clinical trial design and patient counseling. The IMDC criteria risk categories seem to stratify patients into appropriate favourable, intermediate, and poor risk groups, although larger patient numbers are required. It appears that outcomes between metastatic chrRCC and ccRCC are similar when treated with conventional targeted therapies. Patients with metastatic chrRCC can be treated with tyrosine kinase inhibitors and enrolled in clinical trials to further measure outcomes in this rare patient population. © 2017 - IOS Press and the authors. All rights reserved

Published
2017

45. Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk

Author

Beuselinck, B., primary, Verbiest, A., additional, Couchy, G., additional, Job, S., additional, de Reyniès, A., additional, Caruso, S., additional, Verkarre, V., additional, Rioux-Leclercq, N., additional, Schöffski, P., additional, Vano, Y., additional, Elaidi, R.-T., additional, Lerut, E., additional, Albersen, M., additional, Oudard, S., additional, and Zucman-Rossi, J., additional

Published
2018
Full Text
View/download PDF

46. Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors

Author

Graham, J., primary, Wells, J.C., additional, McKay, R., additional, Vaishampayan, U.N., additional, Hansen, A., additional, Donskov, F., additional, Bjarnason, G.A., additional, Beuselinck, B., additional, De Velasco, G., additional, Duh, M.S., additional, Huynh, L., additional, Chang, R., additional, Zanotti, G., additional, Ramaswamy, K., additional, Choueiri, T.K., additional, and Heng, D.Y.C., additional

Published
2018
Full Text
View/download PDF

48. Efficacy of CDK 4/6 inhibition after fulvestrant in metastatic breast cancer

Author

Hoste, G., primary, Punie, K., additional, Wildiers, H., additional, Neven, P., additional, Vergote, I., additional, Beuselinck, B., additional, Concin, N., additional, Han, S., additional, Van Nieuwenhuysen, E., additional, Salihi, R., additional, Smeets, A., additional, Berteloot, P., additional, Lefever, I., additional, Nevelsteen, I., additional, Van Limbergen, E., additional, Weltens, C., additional, and Janssen, H., additional

Published
2018
Full Text
View/download PDF

49. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)

Author

Yip, SM, Ruiz Morales, JM, Donskov, F, Fraccon, A, Basso, U, Rini, BI, Lee, JL, Bjarnason, GA, Sim, HW, Beuselinck, B, Kanesvaran, R, Brugarolas, J, Koutsoukos, K, Fu, SYF, Yuasa, T, Davis, I, Alva, A, Kollmannsberger, C, Choueiri, TK, Heng, DYC, Yip, SM, Ruiz Morales, JM, Donskov, F, Fraccon, A, Basso, U, Rini, BI, Lee, JL, Bjarnason, GA, Sim, HW, Beuselinck, B, Kanesvaran, R, Brugarolas, J, Koutsoukos, K, Fu, SYF, Yuasa, T, Davis, I, Alva, A, Kollmannsberger, C, Choueiri, TK, and Heng, DYC

Abstract

Background: Treatment outcomes are poorly characterized in patients with metastatic chromophobe renal cell cancer (chrRCC), a subtype of renal cell carcinoma. Objective: This retrospective series aims to determine metastatic chrRCC treatment outcomes in the targeted therapy era. Methods: A retrospective data analysis was performed using the IMDC dataset of 4970 patients to determine metastatic chrRCC treatment outcomes in the targeted therapy era. Results: 109/4970 (2.2%) patients had metastatic chrRCC out of all patients with mRCC treated with targeted therapy. These patients were compared with 4861/4970 (97.8%) clear cell mRCC (ccRCC) patients. Patients with metastatic chrRCC had a similar OS compared to patients with ccRCC (23.8 months (95% CI 16.7 - 28.1) vs 22.4 months (95% CI 21.4 - 23.4), respectively (p = 0.0908). Patients with IMDC favorable (18%), intermediate (59%) and poor risk (23%) had median overall survivals of 31.4, 27.3, and 4.8 months, respectively (p = 0.028). Conclusions: To the authors' knowledge, this is the largest series of metastatic chrRCC patients and these results set new benchmarks for survival in clinical trial design and patient counseling. The IMDC criteria risk categories seem to stratify patients into appropriate favourable, intermediate, and poor risk groups, although larger patient numbers are required. It appears that outcomes between metastatic chrRCC and ccRCC are similar when treated with conventional targeted therapies. Patients with metastatic chrRCC can be treated with tyrosine kinase inhibitors and enrolled in clinical trials to further measure outcomes in this rare patient population.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results